Longhua Hospital Shanghai University of Traditional Chinese Medicine
Shanghai, Shanghai Municipality, 200032, China
Location status: Recruiting
NCT Number: NCT05798403
Through a scientific and standardized multicenter, blinding, double-dummy, randomized controlled, noninferiority clinical trial study method, the investigators evaluated electroacupuncture as a safe and effective non-pharmacological treatment for OAB in women by comparison with Solifenacin Succinate.
Interested in participating?
Request Info18 year–75 year
Female
Interventional
Not applicable
Shanghai, Shanghai Municipality, 200032, China
Location status: Recruiting
Epidemiological researches have shown that approximately 500 million people worldwide are affected by OAB, 2 3 with a higher incidence in women than that in men. Pharmacological treatment remains the usual method of clinical treatment. However, some Pharmacologphy has certain side effects, such as blurred consciousness, dry mouth, constipation, and so on, which have limited its widespread clinical use. Therefore, the treatment of OAB needs comprehensive consideration in clinical practice, which deserves our attention and active exploration of other effective treatment methods to relieve patients' pain.Electroacupuncture can effectively improve the clinical symptoms of OAB. As for the comparison between electroacupuncture and medication for the treatment of OAB in women, the results are inconclusive based on the limited research evidence. The aim of the study is to investigate the effectiveness and safety of electroacupuncture compared to Solifenacin Succinate.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
All acupuncture locations will be sterilized on a routine basis. As acupuncture needles are inserted, all needles will be lifting, twirling, and thrusting to reach de qi, a sensation generally associated with acupuncture, including swelling, soreness, numbness, and heaviness.
An electrical stimulator is applied to ipsilateral BL32 and BL35 (KI12 and ST28) with continuous waves of 30 Hz and currents of 1 to 5.0 mA. During the study, oral Solifenacin Succinate placebo will be used.
Other names: placebo medication
During the study, participants will take Solifenacin Succinate. The acupuncture points are the same as the electroacupuncture group, without the insertion of needles. The procedures, electrode positions and other treatment settings are the same as the electroacupuncture group, without the skin penetration, power output or needle manipulation of the de qi. At the end of the treatment, the acupuncturist will press the acupuncture point with a dry cotton ball to allow the patient to feel the "needles"being pulled out.
Other names: Sham electroacupuncture
Time frame: At week 4 (end of treatment).
The percentage change in the number of voids every 24 hours at week 4 compared to baseline. It is measured by a three-day voiding diary.
Time frame: At week 2, week 8(follow-up) and week 16 (follow-up).
The percentage change in the number of voids every 24 hours at 2th, 8th and 16th weeks of the trail.It is measured by a three-day voiding diary.
Time frame: At week 2, 4 (end of treatment), week 8(follow-up) and week 16 (follow-up).
The OABSS assessed the occurrence of daytime voiding, nocturnal voiding, urgency and urge incontinence in patients during the last week.
Time frame: At week 2, 4 (end of treatment), week 8(follow-up) and week 16 (follow-up).
The number of urinary incontinence and urgency every 24 hours based on a three-day voiding diary.
Time frame: At baseline and week 4 (end of treatment).
The OAB-q is an observation of the severity and frequency of bladder-related symptoms in patients over the past four weeks.
Time frame: At baseline and week 4 (end of treatment).
The GAD-7 is used to assess subjects' anxiety.
Time frame: At baseline and week 4 (end of treatment).
The HRQoL will be measured by the King's Health Questionnaire (KHQ).
Time frame: At week 2, 4 (end of treatment), week 8(follow-up) and week 16 (follow-up).
It will be evaluated using a four-point scale, which is level 0 (not at all helpful), level 1 (a little helpful), level 2 (moderately helpful) and level 3 (very helpful).
Time frame: During 1-4 weeks.
Observe the incidence of adverse events during the treatment.
Time frame: Within 5 minutes after the first, sixth and twelfth acupuncture treatment.
Visual analog scale (VAS) will be used to evaluate the degree of discomfort during treatment. The scale ranging from 0 to 10cm, with 0cm indicating no discomfort and 10cm indicating severe discomfort. Evaluation time: The average value of the first and ninth acupuncture treatments was taken within 5 minutes after the end of the two treatments. If the VAS value is missing in one of the cases, another is taken as the result.
Time frame: Within 5 minutes after the first and ninth acupuncture treatment.
0=very difficult to accept, 1=slightly difficult to accept, 2=acceptable, 3=easy to accept, 4=very easy to accept. Evaluation time: The average value of the first and ninth acupuncture treatments was taken within 5 minutes after the end of the two treatments. If the VAS value is missing in one of the cases, another is taken as the result.
Time frame: At the end of the 12th session of acupuncture treatment
Six options will be offered by an independent assessor in an interrogative manner: electroacupuncture, sham electroacupuncture and indeterminate; medication, placebo treatment and indeterminate. The patients' answers will be statistically analyzed to assess the success of the blinded implementation.
Contact information is provided by the study sponsor or research team.
PING YIN
CONTACT
YUELAI CHEN
CONTACT
Yin Ping
Other
Electroacupuncture Versus Solifenacin Succinate for Female Overactive Bladder: A Multicenter, Randomized, Controlled, Noninferiority Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06511141
Benign Prostatic Hyperplasia, Female Urogenital Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT04873037
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Royal Oak, Michigan, United States
View Trial DetailsNCT05878951
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Chicago, Illinois, United States
View Trial DetailsNCT07432659
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Charleston, South Carolina, United States
View Trial Details